Bristol/Gilead Triple Combination HIV Therapy Has Back-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb and Gilead are developing a "back-up" formulation of the fixed-dose combination of Sustiva and Truvada that is the subject of their joint venture
You may also be interested in...
Truvada Growth Driven By Placement On First-Line Regimens, Gilead Says
Truvada (emtricitabine/tenofovir disoproxil) brand awareness is close to 100% among HIV treatment community partly due to direct-to-consumer ads, which will continue throughout 2005, Gilead says. Most growth comes from treatment-naive patients, followed by Viread and Emtriva switches, firm says.
Truvada Growth Driven By Placement On First-Line Regimens, Gilead Says
Truvada (emtricitabine/tenofovir disoproxil) brand awareness is close to 100% among HIV treatment community partly due to direct-to-consumer ads, which will continue throughout 2005, Gilead says. Most growth comes from treatment-naive patients, followed by Viread and Emtriva switches, firm says.
Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
The joint venture is expected to use a new brand name for the fixed-dose combination of Sustiva and Truvada. Bristol and Gilead will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products.”